| Literature DB >> 33659345 |
Akhilesh Kumar1, Saritha S D'Souza1, Gene Uenishi1, Mi Ae Park1, Jeong Hee Lee1, Igor I Slukvin1,2,3.
Abstract
Pluripotent stem cells (PSCs) have the potential to provide homogeneous cell populations of T cells that can be grown at a clinical scale and genetically engineered to meet specific clinical needs. OP9-DLL4, a stromal line ectopically expressing the Notch ligand Delta-like 4 (DLL4) is used to support differentiation of PSCs to T-lymphocytes. This article outlines several protocols related to generation of T cells from human and non-human primate (NHP) PSCs, including initial hematopoietic differentiation of PSC on OP9 feeders or defined conditions, followed by coculture of the OP9-DLL4 cells with the PSC-derived hematopoietic progenitors (HPs), leading to efficient differentiation to T lymphocytes. In addition, we describe a protocol for robust T cell generation from hPSCs conditionally expressing ETS1. The presented protocols provide a platform for T cell production for disease modeling and evaluating their use for immunotherapy in large animal models.Entities:
Keywords: Hematopoietic differentiation; Hematopoietic progenitor; Hemogenic endothelium; Human embryonic stem cells; Human pluripotent stem cells; Non-human primate pluripotent stem cells; T cells
Year: 2020 PMID: 33659345 PMCID: PMC7842311 DOI: 10.21769/BioProtoc.3675
Source DB: PubMed Journal: Bio Protoc ISSN: 2331-8325